Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical safety of neostigmine vs sugammadex for reversal of rocuronium-induced neuromuscular block
2009-013537-22Phase 3Completed
- Sponsor
- Klaus Olkkola
- Start
- Jun 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3 trial of Sugammadex and neostigmine in surgical condition (2 arms), sponsored by Klaus Olkkola. Primary endpoint: Time to TOF ratio 0.90 after reversal. Started Jun 2009; status: completed.
02
Drugs
Sugammadexneostigmine
03
Conditions
surgical condition
Beyond the preview
Go deeper on 2009-013537-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013537-22.